Cargando…
FGF19 and FGF21: In NASH we trust
OBJECTIVE: FGF19 and FGF21 have shown therapeutic promise since their discovery, attested by the fact there are at least 5 assets that activate the FGFR/KLB pathway and one FGF19 analog in clinical development. METHODS: We performed a detailed analyses of published preclinical and clinical data to o...
Autores principales: | Talukdar, Saswata, Kharitonenkov, Alexei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085573/ https://www.ncbi.nlm.nih.gov/pubmed/33383173 http://dx.doi.org/10.1016/j.molmet.2020.101152 |
Ejemplares similares
-
Inventing new medicines: The FGF21 story()
por: Kharitonenkov, Alexei, et al.
Publicado: (2013) -
Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo
por: Adams, Andrew C., et al.
Publicado: (2012) -
FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
por: Henriksson, Emma, et al.
Publicado: (2020) -
FGF21 Requires βklotho to Act In Vivo
por: Adams, Andrew C., et al.
Publicado: (2012) -
Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity
por: Agrawal, Archita, et al.
Publicado: (2018)